Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mitsubishi Tanabe Pharma
Pharma
FDA snubs AbbVie's blockbuster-to-be Parkinson's drug
Analysts have projected ABBV-951’s peak sales will reach $1 billion, but one team of analysts sees the potential for it to reach $2 billion or more.
Angus Liu
Mar 22, 2023 11:50am
Mitsubishi scores $940M from Novartis in arbitration case
Feb 17, 2023 4:40pm
Sanofi-Innovent, Astellas, AbbVie-Sosei—Fierce Pharma Asia
Aug 5, 2022 10:39am
Mitsubishi Tanabe models economic impact of IV-to-oral switch
Aug 2, 2022 7:40am
BeiGene, Legend, Eisai-Biogen—Fierce Pharma Asia
Jul 8, 2022 10:29am
Amylyx's first approval may carry a steep price, ICER argues
Jun 15, 2022 9:46am
